RxDoctor Payments DataLook up a doctor →

Thomas Mayer, MD

Interventional Cardiology · Bannockburn, ILNPI 1013937150

Payments from drug & device makers

$48,930in general payments, 2019–2025

Across 748 payments — averaging $65.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$15K
  • AstraZeneca$13K
  • Novo Nordisk$3K
  • Amgen$3K
  • Novartis$3K
  • Boston Scientific$2K
  • plus $10K from 34 others

What the payments were for

  • Speaking & faculty fees$22,65046%
  • Travel & lodging$2,0974%
  • Food & beverage$24,17049%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,930 in reported general payments places this provider in the 80th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$284,531
Medicare patients
1,166
Services billed
2,905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban218$322,541
VyndaqelTafamidis Meglumine14$304,498
XareltoRivaroxaban167$236,855
EntrestoSacubitril/Valsartan61$85,082
Repatha SureclickEvolocumab68$78,980
JardianceEmpagliflozin40$62,207
WegovySemaglutide29$38,555
OzempicSemaglutide29$27,195
FarxigaDapagliflozin Propanediol14$21,524
Repatha SyringeEvolocumab15$21,324
VascepaIcosapent Ethyl17$17,462
BrilintaTicagrelor14$14,385
Rosuvastatin Calcium728$11,479
Ezetimibe381$11,087
Atorvastatin Calcium754$8,855

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndaqel$844$627,039232 claims
Johnson & JohnsonXarelto$15,431$236,855167 claims
NovartisEntresto$2,610$85,08261 claims
Novo NordiskWegovy, Ozempic$3,060$65,75058 claims
Boehringer IngelheimJardiance$1,465$62,20740 claims
AstraZenecaFarxiga, Brilinta$13,378$35,90928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Bannockburn

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →